<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Intractable Rare Dis Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Intractable Rare Dis Res</journal-id>
<journal-id journal-id-type="publisher-id">irdr</journal-id>
<journal-id journal-id-type="hwp">irdr</journal-id>
<journal-title-group>
<journal-title>Intractable &amp; Rare Diseases Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">2186-3644</issn>
<issn pub-type="epub">2186-361X</issn>
<publisher>
<publisher-name>International Research and Cooperation Association for Bio &amp; Socio-Sciences Advancement</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27904820</article-id>
<article-id pub-id-type="pmc">5116860</article-id>
<article-id pub-id-type="doi">10.5582/irdr.2016.01082</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The neurobiology of the Prader-Willi phenotype of fragile X syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Muzar</surname>
<given-names>Zukhrofi</given-names>
</name>
<xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>§</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lozano</surname>
<given-names>Reymundo</given-names>
</name>
<xref ref-type="aff" rid="a3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>§</sup>
</xref>
<xref ref-type="corresp" rid="c1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kolevzon</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="a3">
<sup>3,c,e,f</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi J.</given-names>
</name>
<xref ref-type="aff" rid="a3">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c1">*</xref>
</contrib>
<aff id="a1"><label>1</label><sup>a)</sup>Medical Investigation of Neurodevelopmental Disorders MIND Institute, <sup>b)</sup>Department of Pediatrics, UC Davis Medical Center, Sacramento, CA, USA</aff>
<aff id="a2"><label>2</label> Department of Histology, Universitas Muhammadiyah Sumatera Utara (UMSU) Faculty of Medicine, Medan, North Sumatera, Indonesia</aff>
<aff id="a3"><label>3</label><sup>c)</sup>Seaver Autism Center for Research and Treatment, <sup>d)</sup>Departments of Genetics and Genomic Sciences, <sup>e)</sup>Psychiatry, and <sup>f)</sup>Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</aff>
</contrib-group>
<author-notes>
<fn fn-type="equal" id="fn1">
<label>§</label>
<p>These authors contributed equally to this works.</p>
</fn>
<corresp id="c1"><label>*</label><italic>Address correspondence to:</italic> Dr. Reymundo Lozano, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY 10025, USA. E-mail: <email>Reymundo.lozano@mssm.edu</email> Dr. Randi J. Hagerman, MIND Institute, UC Davis Health System, 2825 50th Street, Sacramento, CA 95817, USA. E-mail: <email>rjhagerman@ucdavis.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2016</year>
</pub-date>
<volume>5</volume>
<issue>4</issue>
<fpage>255</fpage>
<lpage>261</lpage>
<history>
<date date-type="received">
<day>9</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>7</day>
<month>11</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>2016, International Research and Cooperation Association for Bio &amp; Socio-Sciences Advancement</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<abstract>
<title>Summary</title>
<p>Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and autism, caused by a CGG expansion to greater than 200 repeats in the promoter region of <italic>FMR1</italic> on the bottom of the X chromosome. A subgroup of individuals with FXS experience hyperphagia, lack of satiation after meals and severe obesity, this subgroup is referred to have the Prader-Willi phenotype of FXS. Prader-Willi syndrome is one of the most common genetic severe obesity disorders known and it is caused by the lack of the paternal 15q11–13 region. Affected individuals suffer from hyperphagia, lack of satiation, intellectual disability, and behavioral problems. Children with fragile X syndrome Prader-Willi phenotye and those with Prader Willi syndrome have clinical and molecular similarities reviewed here which will impact new treatment options for both disorders.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>Fragile X syndrome (FXS)</kwd>
<kwd>Prader-Willi phenotype</kwd>
<kwd><italic>FMR1</italic> gene</kwd>
<kwd>Hyperphagia</kwd>
<kwd>Autism</kwd>
<kwd>IGF-1</kwd>
<kwd>Growth hormone</kwd>
</kwd-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="0"></table-count>
<ref-count count="71"></ref-count>
<page-count count="7"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>